NASDAQ:IART - Integra LifeSciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $71.83
  • Forecasted Upside: 32.78 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$54.10
▼ -0.19 (-0.35%)

This chart shows the closing price for IART by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Integra LifeSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IART and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IART

Analyst Price Target is $71.83
▲ +32.78% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Integra LifeSciences in the last 3 months. The average price target is $71.83, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 32.78% upside from the last price of $54.10.

This chart shows the closing price for IART for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Integra LifeSciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022CitigroupLower Price TargetNeutral$70.00 ➝ $67.00N/A
4/13/2022Truist FinancialDowngradeBuy ➝ Hold$72.00 ➝ $71.00Low
2/23/2022Piper SandlerLower Price Target$72.00 ➝ $66.00Medium
1/18/2022Bank of AmericaBoost Price TargetUnderperform$55.00 ➝ $65.00Low
12/17/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$75.00High
11/3/2021Credit Suisse GroupBoost Price TargetOutperform$84.00 ➝ $87.00Low
11/3/2021JMP SecuritiesReiterated RatingBuyLow
9/15/2021BTIG ResearchDowngradeBuy ➝ NeutralLow
6/24/2021Raymond JamesReiterated RatingHoldHigh
4/29/2021CitigroupBoost Price Target$70.00 ➝ $78.00Low
4/29/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$68.00 ➝ $74.00Medium
4/29/2021OppenheimerBoost Price TargetOutperform$79.00 ➝ $88.00Medium
2/25/2021Credit Suisse GroupBoost Price TargetOutperform$73.00 ➝ $79.00Medium
2/19/2021CitigroupBoost Price Target$60.00 ➝ $70.00Low
1/29/2021Piper SandlerBoost Price TargetNeutral$47.00 ➝ $65.00High
1/27/2021JMP SecuritiesBoost Price TargetOutperform$65.00 ➝ $80.00High
1/19/2021BTIG ResearchBoost Price TargetBuy$66.00 ➝ $72.00High
1/7/2021Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$60.00 ➝ $73.00N/A
1/6/2021Truist FinancialBoost Price Target$60.00 ➝ $70.00N/A
12/17/2020OppenheimerBoost Price Target$64.00 ➝ $72.00Low
12/17/2020BTIG ResearchBoost Price TargetBuy$59.00 ➝ $66.00Medium
10/29/2020Piper SandlerLower Price TargetNeutral$53.00 ➝ $47.00Low
10/29/2020OppenheimerInitiated CoverageBuy$64.00Medium
10/8/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$55.00 ➝ $50.00High
9/30/2020Raymond JamesReiterated RatingHoldMedium
9/29/2020OppenheimerReiterated RatingBuy$68.00Medium
8/12/2020Truist FinancialBoost Price Target$55.00 ➝ $60.00Low
8/11/2020Credit Suisse GroupBoost Price TargetOutperform$58.00 ➝ $60.00High
8/11/2020UBS GroupBoost Price TargetNeutral$51.00 ➝ $53.00High
8/11/2020OppenheimerBoost Price TargetOutperform$60.00 ➝ $68.00High
7/10/2020Credit Suisse GroupReiterated RatingBuy$58.00Low
6/26/2020Credit Suisse GroupReiterated RatingBuy$58.00High
5/27/2020CitigroupInitiated CoverageNeutral$54.00Low
5/8/2020UBS GroupLower Price TargetNeutral$65.00 ➝ $55.00Low
5/8/2020Credit Suisse GroupBoost Price TargetOutperform$56.00 ➝ $58.00Low
5/8/2020JMP SecuritiesLower Price TargetMarket Outperform$75.00 ➝ $65.00Low
5/7/2020BTIG ResearchReiterated RatingBuyMedium
4/8/2020BTIG ResearchLower Price TargetBuy$70.00 ➝ $59.00High
4/7/2020Piper SandlerReiterated RatingHold$58.00High
4/6/2020Wells Fargo & CompanyLower Price TargetEqual Weight$62.00 ➝ $46.00High
4/2/2020SunTrust BanksInitiated CoverageBuy$55.00Medium
3/6/2020Credit Suisse GroupLower Price TargetOutperform$70.00 ➝ $65.00Low
2/20/2020UBS GroupBoost Price TargetNeutral$64.00 ➝ $65.00Medium
1/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$59.00 ➝ $58.00Low
1/7/2020Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$59.00 ➝ $58.00Low
1/3/2020SunTrust BanksInitiated CoverageBuy$56.00Low
12/18/2019UBS GroupBoost Price TargetNeutral$63.00 ➝ $65.00Low
10/25/2019OppenheimerSet Price TargetBuy$68.00N/A
10/25/2019Royal Bank of CanadaSet Price TargetHold$62.00N/A
10/25/2019Wells Fargo & CompanySet Price TargetHold$62.00N/A
10/8/2019Wells Fargo & CompanyLower Price TargetMarket Perform$68.00 ➝ $65.00High
7/26/2019Royal Bank of CanadaSet Price TargetHold$66.00Low
7/25/2019OppenheimerBoost Price TargetOutperform$65.00 ➝ $70.00Medium
7/25/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$55.00 ➝ $68.00Medium
7/25/2019JMP SecuritiesBoost Price Target$75.00Medium
7/24/2019BTIG ResearchSet Price TargetBuy$70.00Low
4/25/2019OppenheimerLower Price TargetOutperform$70.00 ➝ $65.00Low
3/19/2019OppenheimerReiterated RatingBuyLow
2/27/2019JMP SecuritiesReiterated RatingBuy$62.00Low
2/22/2019Morgan StanleySet Price TargetHold$57.00Medium
2/21/2019Cantor FitzgeraldReiterated RatingHold$50.00High
1/8/2019Cantor FitzgeraldSet Price TargetHold$54.00Low
1/3/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$56.00High
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$57.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$58.00High
11/2/2018CitigroupLower Price TargetNeutral ➝ Neutral$66.00 ➝ $60.00Low
11/2/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$66.00 ➝ $62.00Low
11/1/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$61.00 ➝ $55.00High
11/1/2018Cantor FitzgeraldLower Price TargetNeutral ➝ Neutral$59.00 ➝ $54.00High
10/31/2018OppenheimerReiterated RatingBuy$70.00High
10/11/2018Morgan StanleySet Price TargetHold$58.00 ➝ $68.00Low
10/11/2018BTIG ResearchReiterated RatingBuy$69.00Medium
10/2/2018OppenheimerReiterated RatingBuyLow
9/12/2018BTIG ResearchReiterated RatingBuy$69.00Medium
8/17/2018OppenheimerReiterated RatingBuyLow
8/7/2018Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
7/26/2018BTIG ResearchUpgradeNeutral ➝ Buy$69.00Medium
7/25/2018Cantor FitzgeraldReiterated RatingHold$59.00Medium
7/25/2018OppenheimerReiterated RatingBuy$74.00High
7/2/2018CitigroupDowngradeBuy ➝ Neutral$64.00 ➝ $66.00High
6/12/2018Cantor FitzgeraldReiterated RatingHold$59.00Low
6/1/2018OppenheimerSet Price TargetBuy$74.00High
5/22/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$57.00 ➝ $65.00Low
5/1/2018OppenheimerSet Price TargetBuy$70.00Low
4/26/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$53.00 ➝ $58.00Low
4/26/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $57.00Low
4/26/2018CitigroupBoost Price TargetOutperform$60.00 ➝ $70.00Low
4/25/2018OppenheimerReiterated RatingBuyLow
4/11/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$50.00 ➝ $55.00Low
4/5/2018BTIG ResearchInitiated CoverageNeutral$56.00Low
3/29/2018OppenheimerSet Price TargetBuy$58.00N/A
3/22/2018OppenheimerReiterated RatingBuyMedium
3/1/2018Jefferies Financial GroupReiterated RatingBuy$63.00Low
2/28/2018OppenheimerSet Price TargetBuy$60.00High
2/28/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$57.00 ➝ $60.00Medium
1/11/2018OppenheimerReiterated RatingBuyMedium
1/9/2018BarclaysReiterated RatingHold$53.00Low
1/5/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$52.00Medium
1/2/2018UBS GroupDowngradeMarket PerformLow
1/2/2018Raymond JamesReiterated RatingOutperform ➝ Market Perform$55.00Medium
1/2/2018Bank of AmericaDowngradeBuy ➝ NeutralHigh
12/12/2017OppenheimerSet Price TargetBuy$58.00Low
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$48.00 ➝ $50.00N/A
10/31/2017UBS GroupReiterated RatingBuy$57.00N/A
10/29/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
10/29/2017Jefferies Financial GroupReiterated RatingBuy$56.00N/A
10/27/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$44.00N/A
10/26/2017OppenheimerReiterated RatingBuyN/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$58.00N/A
9/18/2017OppenheimerReiterated RatingBuy$60.00Low
9/12/2017BarclaysReiterated RatingEqual Weight$47.00 ➝ $53.00High
9/10/2017Jefferies Financial GroupReiterated RatingBuyMedium
7/27/2017Raymond JamesBoost Price TargetOutperform$51.00 ➝ $55.00Low
7/26/2017Cantor FitzgeraldSet Price TargetBuy$65.00Low
7/26/2017OppenheimerReiterated RatingBuyLow
7/10/2017Cantor FitzgeraldReiterated RatingOverweight$65.00Low
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/7/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/7/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Integra LifeSciences logo
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $54.10
Low: $53.99
High: $54.88

50 Day Range

MA: $58.52
Low: $53.86
High: $62.64

52 Week Range

Now: $54.10
Low: $53.22
High: $76.70

Volume

10,262 shs

Average Volume

489,537 shs

Market Capitalization

$4.50 billion

P/E Ratio

29.51

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Integra LifeSciences?

The following Wall Street analysts have issued reports on Integra LifeSciences in the last year: Bank of America Co., BTIG Research, Citigroup Inc., Credit Suisse Group AG, JMP Securities, JPMorgan Chase & Co., Piper Sandler, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for IART.

What is the current price target for Integra LifeSciences?

0 Wall Street analysts have set twelve-month price targets for Integra LifeSciences in the last year. Their average twelve-month price target is $71.83, suggesting a possible upside of 32.3%.
View the latest price targets for IART.

What is the current consensus analyst rating for Integra LifeSciences?

Integra LifeSciences currently has 1 sell rating, 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IART, but not buy more shares or sell existing shares.
View the latest ratings for IART.

How do I contact Integra LifeSciences' investor relations team?

Integra LifeSciences' physical mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company's listed phone number is (609) 275-0500 and its investor relations email address is [email protected] The official website for Integra LifeSciences is www.integralife.com. Learn More about contacing Integra LifeSciences investor relations.